Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Assets (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Current Assets readings, the most recent being $160.1 million for Q1 2026.

  • Quarterly Current Assets rose 248.74% to $160.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $160.1 million through Mar 2026, up 248.74% year-over-year, with the annual reading at $74.4 million for FY2025, 32.94% up from the prior year.
  • Current Assets hit $160.1 million in Q1 2026 for Ovid Therapeutics, up from $74.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $170.1 million in Q1 2022 and bottomed at $28.8 million in Q3 2025.
  • Average Current Assets over 5 years is $98.1 million, with a median of $93.2 million recorded in 2024.
  • The largest annual shift saw Current Assets crashed 56.21% in 2025 before it surged 248.74% in 2026.
  • Ovid Therapeutics' Current Assets stood at $131.4 million in 2022, then decreased by 16.58% to $109.6 million in 2023, then plummeted by 48.96% to $55.9 million in 2024, then skyrocketed by 32.94% to $74.4 million in 2025, then soared by 115.34% to $160.1 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Current Assets are $160.1 million (Q1 2026), $74.4 million (Q4 2025), and $28.8 million (Q3 2025).